Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies — Stella

Recruiting

Back to Melanoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

United States

UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

Key details

Phase

Safety & dosing

Sponsor

Dan Zandberg

Enrollment target

~72 participants

Started

September 2020

Primary completion

April 2032

Age range

18 Years and older

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov